



## Banzel® (rufinamide) – First-time generic

- On November 4, 2020, [Hikma Pharmaceuticals USA](#) launched an [AB-rated](#) generic version of Eisai's [Banzel \(rufinamide\)](#) oral suspension.
  - Bionpharma also received FDA approval of an [AB-rated](#) generic version of Banzel oral suspension on April 23, 2019. Launch plans are pending.
- Banzel is approved for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
- Banzel is also available as a brand tablet and carries the same indication as Banzel suspension.
- According to IQVIA, U.S. sales of Banzel oral suspension were approximately \$125 million in the 12 months ending September 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.